The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. The five-year dividend growth rate is just below 18%. The major market events for the week ahead right in your inbox. About the AbbVie, Inc. stock forecast. Date. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. on the strength of its future rather than present portfolio. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. You should never invest money you cannot afford to lose. What is a Good Dividend Yield? Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. AbbVie has received a consensus rating of Hold. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. . The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. The most recent increase was . The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. I write about Biotech, Pharma and Healthcare stocks and share investment tips. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. I am not receiving compensation for it (other than from Seeking Alpha). The pharma industry witnessed solid growth amid the pandemic. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. I have no business relationship with any company whose stock is mentioned in this article. The difference between trading assets and CFDs. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. (AbbVie JPM Healthcare conference presentation). Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. The company didn't offer a . Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. You should consider whether you understand how CFDs work and can afford the risks. The lowest target is $136.35 and the highest is $210. There are currently 9 hold ratings and 7 buy ratings for the stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. AbbVie product revenues by quarter and year since FY20. The company provided earnings per share (EPS) guidance of $10.70- for the period. For the next eight years, the forecast is for Free Cash Flow to grow by . Teliso V is an antibody drug conjugate and a c-Met inhibitor. AbbVie's stock is owned by many different institutional and retail investors. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Gene therapies have been a long time coming, having first been popularized in the early noughties. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. Their ABBV share price forecasts range from $140.00 to $200.00. Get short term trading ideas from the MarketBeat Idea Engine. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. AbbVie is a leader in ESG and sustainability. During the same quarter in the prior year, the firm posted $3.31 EPS. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. This year is off to a strong start. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. This could present more profit potential for drugmakers as well as investors. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. On average, they predict the company's stock price to reach $161.12 in the next year. Forecast . Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. Shares are consolidating with a buy. The company issued revenue guidance of -. This indicates that the company will be able to sustain or increase its dividend. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Different trading strategies will suit different investment goals with short or long-term focus. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. ABBV Stock 12 Months Forecast. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. contact@marketbeat.com That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. I wrote this article myself, and it expresses my own opinions. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. This suggests a possible upside of 3.2% from the stock's current price. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. AbbVie has 5 focus areas for its research and products. AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. If you rely on the information on this page then you do so entirely on your own risk. AbbVie saw a increase in short interest in February. Your current $100 investment may be up to $188.28 in 2028. To date, the company had invested more than $50 billion into research through more than 250 partnerships. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. The median. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. AbbVie Inc. is a US-based biopharma company with global operations. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . These are Immunology, Oncology, Neurology, Virology and Eye Care. That reflects uncertainty about what the future holds for AbbVie. Please. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. The dividend payout ratio of AbbVie is 89.56%. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. I am not receiving compensation for it (other than from Seeking Alpha). (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. In other words, no Humira, no problem! Forecasts shouldnt be used as a substitute for your own research. This indicates that AbbVie will be able to sustain or increase its dividend. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. View the best growth stocks for 2023 here. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! American Consumer News, LLC dba MarketBeat 2010-2023. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Bhd., AbbVie Sp. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. I am not receiving compensation for it (other than from Seeking Alpha). Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. AbbVie has a P/B Ratio of 15.97. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. Only you can design whether Abbvie stock is the right investment for you. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. First of all, as shown in the table above I forecast product sales out to 2030. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. Skyrizi and Rinvoq will together achieve a higher peak sales figure than even Humira could manage, even while Humira is still making a substantial top line contribution, still accounting for as much of 7% of AbbVie's total sales in 2030. 326 E 8th St #105, Sioux Falls, SD 57103 AbbVie declared a quarterly dividend on Thursday, February 16th. The material provided on this website is for information purposes only and should not be understood as an investment advice. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. Let's begin our analysis with the immunology division. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. View which stocks are hot on social media with MarketBeat's trending stocks report. The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. Wallet Investor suggested that the price could hit $300.386 in June 2027. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. Please disable your ad-blocker and refresh. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. ABBV has several positive factors pushing its price performance. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. The stocks growth marks a significant outperformance over the broader markets. My No. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. And never invest or trade money you cannot afford to lose. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. 2022 Cable News Network. I am not receiving compensation for it (other than from Seeking Alpha). In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses.